Deligence Group is the only firm uniting Corporate Paralegal Services, Venture Capital Advisory, and Clinical Research — purpose-built for US-India cross-border operations.
Entity formation, SEC/FEMA compliance, M&A readiness across US & India jurisdictions.
Learn more ›Seed through Series A and M&A exits — $50K to $20M+ funding lifecycle support.
Learn more ›120+ NABH/NABL sites, FDA/EMA compliant Phase I–IV trials, CDSCO submissions.
Learn more ›The US-India economic corridor represents one of the most dynamic cross-border opportunities in global business today. Most firms operate in silos — legal experts lack capital insights, investors miss regulatory nuances, and research institutions struggle with commercialization pathways.
Deligence Group addresses this fragmentation through a revolutionary three-pillar model that creates compounding advantages for clients navigating the complexities of US-India business.
Schedule a free consultation ›Each pillar delivers world-class service independently. Together, they create unmatched compounding strategic advantages.
Expert guidance on optimal corporate structures, ongoing compliance, and operational scaling across US and Indian jurisdictions — far beyond document preparation.
Comprehensive capital strategy from $50K seed rounds to $20M+ growth equity and M&A exits — navigating both US and Indian ecosystems simultaneously.
India conducts 15%+ of worldwide clinical trials with 50–60% cost advantages. We create seamless pathways for pharma, biotech, and medical device companies.
Our integrated model delivers compounding advantages unavailable from any single-discipline firm.
No billing surprises. Transparent retainer structures that scale with your business — saving 60–70% vs. traditional law firms.
We track SEC, FEMA, CDSCO, and ICH-GCP changes before they affect your operations — turning compliance into competitive advantage.
We act as an extension of your in-house team — anticipating needs before they become crises. Proximity-first, always.
Battle-tested operational playbooks from 50+ successful US-India expansions compress your time-to-market by months.
Access India's massive clinical trial infrastructure — 120+ accredited sites — at a fraction of Western costs, FDA/EMA compliant.
One integrated partner with a unified view of your entire journey — no siloed vendors, no communication gaps.
"Deligence didn't just handle our Delaware incorporation — they anticipated our Series A structure 6 months early. That foresight saved us $180K in restructuring costs."
"Their clinical research network gave us Phase II trial sites in 6 Indian cities within 3 weeks. CDSCO submission guidance was flawless and on schedule."
"The integrated model is genuinely different. Legal, capital, and research on one team closed our Series A 40% faster than industry average."
Schedule a no-obligation strategy session. We'll map your cross-border journey and show you exactly where integrated expertise creates decisive advantage.
Our team responds within 24 hours with a tailored overview of how Deligence Group can accelerate your US-India strategy.